American Airlines Group Inc vs AbbVie Inc — how do they compare? American Airlines Group Inc trades at $15.34 (market cap $10.55B), while AbbVie Inc trades at $248.68 (market cap $438.19B). The key difference: AbbVie Inc is far larger — about 41.5× American Airlines Group Inc's market cap, and AbbVie Inc pays a 2.79% dividend while American Airlines Group Inc pays none. Which is the better fit depends on your goals.
| AAL | ABBV | |
|---|---|---|
Market Cap | $10.55B | $438.19B |
Sector | Industrials | Health |
52-Week High | $18.15 | $263.58 |
52-Week Low | $10.18 | $197.38 |
Enterprise Value | $38.51B | $502.45B |
Dividend Yield | — | 2.79% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
Trailing returns across standard periods
Latest headlines on both assets
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →